Spotlight Correspondence
Leukemia (2005) 19, 132–134. doi:10.1038/sj.leu.2403453 Published online 28 October 2004
Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib
R G Piazza1,2, V Magistroni1, M Gasser3, F Andreoni1, A Galietta1, L Scapozza3 and C Gambacorti-Passerini1,4
- 1Department of Experimental Oncology, National Cancer Institute, Milan, Italy
- 2University of Milano Bicocca, S Gerardo Hospital, Monza
- 3Department of Chemistry and Applied BioSciences at the Swiss Federal Institute of Technology, Zurich, Switzerland
- 4Department of Internal Medicine, Section of Hematology, University of Milano Bicocca, San Gerardo Hospital, Monza
Correspondence: Dr C Gambacorti-Passerini, Department of Experimental Oncology, National Cancer Institute, Via Venezian 1, Milan 20133, Italy. Fax: +39 2 2390 3237; E-mail: carlo.gambacorti@istitutotumori.mi.it
Received 24 November 2003; Accepted 4 June 2004; Published online 28 October 2004.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
REVIEWS
Pathogenesis of parkinson's disease: dopamine, vesicles and α-synuclein
Nature Reviews Neuroscience Review (01 Dec 2002)
NEWS AND VIEWS
Inhibitors of Bcr-abl. breaking new ground again
Nature Chemical Biology News and Views (01 Feb 2006)
